Respiratory Updates
前往频道在 Telegram
🟢 To stay up-to-date on pharmacotherapy and other aspects of respiratory diseases🫁 🟢 Thoracic Research Center🔬 🟢 Tehran University of Medical Sciences🎓
显示更多📈 Telegram 频道 Respiratory Updates 的分析概览
频道 Respiratory Updates (@respiratoryupdates) 英语 语言赛道中的 是活跃参与者。目前社区聚集了 19 576 名订阅者,在 医学 类别中位列第 1 180,并在 伊朗 地区排名第 17 244 位。
📊 受众指标与增长动态
自 невідомо 创建以来,项目保持高速增长,吸引了 19 576 名订阅者。
根据 05 九月, 2026 的最新数据,频道保持稳定运转。过去 30 天订阅人数变化为 496,过去 24 小时变化为 27,整体触达仍然可观。
- 认证状态: 未认证
- 互动率 (ER): 平均受众互动率为 20.73%。内容发布后 24 小时内通常能获得 5.14% 的反应,占订阅者总量。
- 帖子覆盖: 每篇帖子平均可获得 4 057 次浏览,首日通常累积 1 007 次浏览。
- 互动与反馈: 受众积极参与,单帖平均反应数为 11。
- 主题关注点: 内容集中在 patient, guideline, edit, reader, society 等核心主题上。
📝 描述与内容策略
作者将该频道定位为表达主观观点的平台:
“🟢 To stay up-to-date on pharmacotherapy and other aspects of respiratory diseases🫁
🟢 Thoracic Research Center🔬
🟢 Tehran University of Medical Sciences🎓”
凭借高频更新(最新数据采集于 06 九月, 2026),频道始终保持新鲜度与高覆盖。分析显示受众积极互动,使其成为 医学 类别中的关键影响点。
19 576
订阅者
+2724 小时
+1157 天
+49630 天
帖子存档
19 576
Repost from Pulmonology pearls
The Lancet Respiratory Medicine
Available online 12 February 2026
In Press, Corrected Proof
Articles
Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials
KALOS and LOGOS study investigators †
https://doi.org/10.1016/S2213-2600(25)00457-6
19 576
Edit, Sign and Share PDF files on the go. Download the Acrobat Reader app: https://adobeacrobat.app.link/Mhhs4GmNsxb
19 576
Repost from Hakimed: Medical Resources
🗞️ Medical Articles
Source: Journal of Allergy and Clinical Immunology: In PracticeTopic: High-dose inhaled steroids after severe asthma flare show no added benefit In a large U.S. retrospective cohort study, stepping up to high-dose inhaled corticosteroids (ICS) after a severe asthma exacerbation did not reduce future exacerbation risk. Among patients on medium-dose ICS, escalation to high-dose was associated with higher annualized exacerbation rates and increased likelihood of another flare. Similar lack of benefit was seen when escalating from low- to high-dose ICS. Findings suggest alternative strategies may be preferable to routine high-dose ICS escalation after exacerbations. Link: https://pubmed.ncbi.nlm.nih.gov/41167528/ @HakimApps_Guideline
19 576
The current state of knowledge on asthma-COPD overlap (ACO) in clinical and experimental research: what do we know so far?
19 576
Repost from Pulmonology pearls
Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. Lung 202, 367–383 (2024). https://doi.org/10.1007/s00408-024-00717-y
19 576
Repost from N/a
Sepsis and Septic Shock during Pregnancy and Postpartum _ ACOG Aug25
19 576
Repost from Pulmonology pearls
BJA Education
Volume 25, Issue 10, October 2025, Pages 391-399
Ventilator-associated pneumonia
https://doi.org/10.1016/j.bjae.2025.07.002
19 576
Repost from Pulmonology pearls
ESICM guidelines on circulatory shock and hemodynamic monitoring 2025. Intensive Care Med (2025). https://doi.org/10.1007/s00134-025-08137-z
19 576
Repost from Pulmonology pearls
Antibiotic therapy for severe bacterial infections. Intensive Care Med 51, 1867–1885 (2025). https://doi.org/10.1007/s00134-025-08063-0
19 576
Repost from Pulmonology pearls
Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 6, June 2025, Pages 1508–1518, https://doi.org/10.1093/jac/dkaf126
19 576
ESICM_Clinical_Practice_Guideline_on_Fluid_Therapy_in_Adult_Critically.pdf3.14 MB
19 576
Repost from Pulmonology pearls
Indian_Guidelines_on_Nebulization_Therapy_2022_Indian_Journal_of.pdf3.58 MB
19 576
Repost from Pulmonology pearls
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease
Developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)
Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)
European Respiratory Journal 2025 2500896; DOI: https://doi.org/10.1183/13993003.02533-2024
19 576
Repost from Pulmonology pearls
Pharmacotherapy-Casebook-A-Patient-Focused-Approach-9.pdf12.43 MB
19 576
Repost from N/a
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy - ICM 25
